Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical Gastroenterology and Hepatology Année : 2022

Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease

(1, 2, 3) , (4) , (5, 6)
1
2
3
4
5
6

Résumé

No abstract available

Dates et versions

hal-03870157 , version 1 (24-11-2022)

Identifiants

Citer

Anthony Buisson, Maria Nachury, Mathurin Fumery. Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease. Clinical Gastroenterology and Hepatology, 2022, ⟨10.1016/j.cgh.2022.11.006⟩. ⟨hal-03870157⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More